GlaxoSmithKline plc (NYSE:GSK) – Jefferies Group issued their FY2022 EPS estimates for shares of GlaxoSmithKline in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford forecasts that the pharmaceutical company will earn $3.75 per share for the year.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.01. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%.
GlaxoSmithKline (NYSE GSK) traded up $0.01 during trading on Wednesday, reaching $38.17. The company had a trading volume of 4,320,000 shares, compared to its average volume of 5,510,000. The stock has a market capitalization of $93,210.00, a PE ratio of 29.14, a PEG ratio of 2.17 and a beta of 0.97. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. GlaxoSmithKline has a 12 month low of $34.52 and a 12 month high of $44.53.
A number of institutional investors and hedge funds have recently modified their holdings of GSK. Principal Financial Group Inc. purchased a new stake in GlaxoSmithKline in the second quarter worth about $602,000. King Luther Capital Management Corp increased its position in GlaxoSmithKline by 1.0% in the second quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after buying an additional 55 shares in the last quarter. Stevens Capital Management LP increased its position in GlaxoSmithKline by 17.1% in the second quarter. Stevens Capital Management LP now owns 40,674 shares of the pharmaceutical company’s stock worth $1,754,000 after buying an additional 5,933 shares in the last quarter. Lazard Asset Management LLC increased its position in GlaxoSmithKline by 5.8% in the second quarter. Lazard Asset Management LLC now owns 42,698 shares of the pharmaceutical company’s stock worth $1,841,000 after buying an additional 2,324 shares in the last quarter. Finally, Quantitative Investment Management LLC purchased a new stake in GlaxoSmithKline in the second quarter worth about $3,221,000. Institutional investors and hedge funds own 9.80% of the company’s stock.
In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of GlaxoSmithKline stock in a transaction on Monday, November 6th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.
The business also recently declared a quarterly dividend, which was paid on Thursday, January 11th. Shareholders of record on Friday, November 10th were given a $0.5037 dividend. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a yield of 5.28%. GlaxoSmithKline’s dividend payout ratio is presently 155.73%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.